JP2020512973A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512973A5
JP2020512973A5 JP2019548287A JP2019548287A JP2020512973A5 JP 2020512973 A5 JP2020512973 A5 JP 2020512973A5 JP 2019548287 A JP2019548287 A JP 2019548287A JP 2019548287 A JP2019548287 A JP 2019548287A JP 2020512973 A5 JP2020512973 A5 JP 2020512973A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
abp
composition according
human tigit
htigit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019548287A
Other languages
English (en)
Japanese (ja)
Other versions
JP7335164B2 (ja
JP2020512973A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/025460 external-priority patent/WO2018183889A1/en
Publication of JP2020512973A publication Critical patent/JP2020512973A/ja
Publication of JP2020512973A5 publication Critical patent/JP2020512973A5/ja
Application granted granted Critical
Publication of JP7335164B2 publication Critical patent/JP7335164B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019548287A 2017-03-30 2018-03-30 抗tigit抗原結合タンパク質及びその使用方法 Active JP7335164B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479042P 2017-03-30 2017-03-30
US62/479,042 2017-03-30
PCT/US2018/025460 WO2018183889A1 (en) 2017-03-30 2018-03-30 Anti-tigit antigen-binding proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2020512973A JP2020512973A (ja) 2020-04-30
JP2020512973A5 true JP2020512973A5 (cg-RX-API-DMAC7.html) 2021-04-30
JP7335164B2 JP7335164B2 (ja) 2023-08-29

Family

ID=62002506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019548287A Active JP7335164B2 (ja) 2017-03-30 2018-03-30 抗tigit抗原結合タンパク質及びその使用方法

Country Status (15)

Country Link
US (1) US11453720B2 (cg-RX-API-DMAC7.html)
EP (1) EP3601340A1 (cg-RX-API-DMAC7.html)
JP (1) JP7335164B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190134605A (cg-RX-API-DMAC7.html)
CN (1) CN110546163B (cg-RX-API-DMAC7.html)
AU (1) AU2018243665A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019018378A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055289A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019009612A2 (cg-RX-API-DMAC7.html)
IL (1) IL269074B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20190203A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019010440A (cg-RX-API-DMAC7.html)
PH (1) PH12019502025A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908092RA (cg-RX-API-DMAC7.html)
WO (1) WO2018183889A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016331052B2 (en) 2015-10-01 2023-08-03 Potenza Therapeutics, Inc. Anti-TIGIT antigen-binding proteins and methods of use thereof
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
IL298946A (en) 2020-06-18 2023-02-01 Genentech Inc Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
PE20230839A1 (es) 2020-06-22 2023-05-19 Ngm Biopharmaceuticals Inc Agentes de union a lair-1 y metodos para su uso
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗tigit抗體、抗cd96抗體及其使用方法
EP4341287A4 (en) * 2021-05-18 2024-12-04 Suzhou Kanova Biopharmaceutical Co., Ltd. ANTI-TIGIT ANTIBODIES AND THEIR USE
CN115466327B (zh) * 2021-06-10 2025-07-08 北京天广实生物技术股份有限公司 结合tigit的抗体及其用途
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス,インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
ES2360479T3 (es) 2000-12-18 2011-06-06 Dyax Corp. Bibliotecas focalizadas de paquetes genéticos.
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20030215914A1 (en) 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2519953C (en) 2003-03-24 2016-01-05 The Scripps Research Institute Dna vaccine against tumor growth and methods of use thereof
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
JP4633788B2 (ja) 2004-04-13 2011-02-16 エフ.ホフマン−ラ ロシュ アーゲー 抗p−セレクチン抗体
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
AU2006261127B2 (en) 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
EP1963534A2 (en) 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
ES2758126T3 (es) 2008-04-09 2020-05-04 Genentech Inc Composiciones y métodos para el tratamiento de enfermedades relacionadas con la inmunidad
CN102666582B (zh) 2009-12-22 2016-03-30 弗·哈夫曼-拉罗切有限公司 序列依赖性聚集
EP2388336A1 (en) 2010-05-19 2011-11-23 Signature Diagnostics AG Method and kits for diagnosing colorectal cancer
CA2802017A1 (en) 2010-06-09 2011-12-15 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
MX360336B (es) 2010-07-16 2018-10-30 Adimab Llc Star Colecciones de anticuerpos.
AU2011320732B2 (en) 2010-10-26 2018-07-05 Mars Incorporated Boronates as arginase inhibitors
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
WO2013184912A2 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
ES2776029T3 (es) * 2012-10-08 2020-07-28 St Jude Childrens Res Hospital Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
HK1210964A1 (en) 2012-12-04 2016-05-13 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
MX384142B (es) * 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
CN113583131B (zh) 2014-08-19 2024-09-03 默沙东有限责任公司 抗tigit抗体
EP3215536A1 (en) 2014-11-06 2017-09-13 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and tigit inhibitors
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Tigitに対する抗体
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit結合劑和彼之用途
US10946095B2 (en) * 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
CN106554347B (zh) 2015-09-25 2020-10-30 浙江博生医药有限公司 Egfr激酶抑制剂及其制备方法和应用
AU2016331052B2 (en) * 2015-10-01 2023-08-03 Potenza Therapeutics, Inc. Anti-TIGIT antigen-binding proteins and methods of use thereof
JOP20190134A1 (ar) * 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
AU2020205753B2 (en) * 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer

Similar Documents

Publication Publication Date Title
JP2020512973A5 (cg-RX-API-DMAC7.html)
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP2021087455A5 (cg-RX-API-DMAC7.html)
JP2018518939A5 (cg-RX-API-DMAC7.html)
JP2020530289A5 (cg-RX-API-DMAC7.html)
JP2019511212A5 (cg-RX-API-DMAC7.html)
JP2018533371A5 (cg-RX-API-DMAC7.html)
JP2017524367A5 (cg-RX-API-DMAC7.html)
JP2024023228A5 (cg-RX-API-DMAC7.html)
JP2016514462A5 (cg-RX-API-DMAC7.html)
JP2019525771A5 (cg-RX-API-DMAC7.html)
WO2019005641A1 (en) GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF
JP2017537629A5 (cg-RX-API-DMAC7.html)
JP2019530431A5 (cg-RX-API-DMAC7.html)
RU2017121892A (ru) Клетка
JP2018532383A5 (cg-RX-API-DMAC7.html)
JP2018532407A5 (cg-RX-API-DMAC7.html)
JP2017527275A5 (cg-RX-API-DMAC7.html)
JP2018504094A5 (cg-RX-API-DMAC7.html)
JP2020514363A5 (cg-RX-API-DMAC7.html)
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
JP2019510733A5 (cg-RX-API-DMAC7.html)
RU2018105963A (ru) Антитело против глипикана-3 и его применение
JP2019513725A5 (cg-RX-API-DMAC7.html)